Strategic partnerships Kemp Proteins has a history of strategic partnerships and acquisitions (Six.02 Bioservices, biosciences collaborations, Columbia Biosciences, AvivoBio and OneCyte) which signals openness to channel, co-development, and joint optimization opportunities that can be leveraged to expand service reach and cross-sell capabilities.

Process-to-GMP readiness Their process discovery services flow into Manufacturing Batch Records for GMP transitions, indicating a strong position to upsell full GMP manufacturing scale-up, regulatory documentation packages, and reference material support for late-stage programs.

Diverse expression platforms Expertise across mammalian, insect, and E. coli systems plus hybridoma and stable cell-line development supports a broad customer base and enables targeted outreach to biotech firms seeking versatile gene-to-protein solutions or platform diversification.

Quality credentials ISO9001 and ISO13485 certified quality management combined with AAALAC accreditation strengthens credibility for regulated diagnostics, therapeutics, and veterinary programs, making Kemp attractive for clients requiring rigorous quality and compliance.

Targeted opportunities Active engagement with vaccine/antibody programs (SARS-CoV-2, Influenza) and ongoing usage by FDA and other clients suggests targeting partners in infectious disease, rapid-response platforms, and antibody discovery programs for collaboration in development and manufacturing support.